Amgen (NASDAQ:AMGN) Issues FY 2026 Earnings Guidance

Amgen (NASDAQ:AMGN) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 21.700-23.100 for the period, compared to the consensus EPS estimate of 22.290. The company issued revenue guidance of $37.1 billion-$38.5 billion, compared to the consensus revenue estimate of $37.8 billion.

Amgen Stock Performance

AMGN stock traded down $16.14 on Friday, hitting $330.11. The company had a trading volume of 2,780,349 shares, compared to its average volume of 2,730,957. Amgen has a 12-month low of $261.43 and a 12-month high of $391.29. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. The stock’s 50-day simple moving average is $358.07 and its 200 day simple moving average is $340.45. The stock has a market cap of $178.15 billion, a price-to-earnings ratio of 23.20, a P/E/G ratio of 3.34 and a beta of 0.47.

Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.73 by $0.42. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company had revenue of $8.62 billion for the quarter, compared to analysts’ expectations of $8.58 billion. During the same quarter last year, the company posted $4.90 earnings per share. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, equities research analysts expect that Amgen will post 22.16 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be issued a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a yield of 3.1%. Amgen’s dividend payout ratio (DPR) is currently 70.84%.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on AMGN shares. Rothschild & Co Redburn raised their target price on shares of Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a report on Wednesday, February 18th. Leerink Partners restated a “market perform” rating and issued a $355.00 target price on shares of Amgen in a report on Thursday, March 5th. Canaccord Genuity Group started coverage on shares of Amgen in a report on Monday, April 20th. They issued a “hold” rating and a $366.00 target price on the stock. Daiwa Securities Group raised their target price on shares of Amgen from $370.00 to $410.00 and gave the stock an “outperform” rating in a report on Tuesday, February 10th. Finally, Wall Street Zen cut shares of Amgen from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $357.54.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q1 beat and strong product momentum — Amgen topped EPS and revenue estimates, said 16 drugs delivered double‑digit gains and raised its FY outlook, supporting the long‑term growth thesis. Amgen’s Q1 Earnings Top Estimates
• Positive Sentiment: Goldman raises price target to $425 and keeps a Buy — a sizable analyst upgrade that signals confidence in execution and the pipeline, offering potential upside over the medium term. Goldman Sachs Adjusts Amgen Price Target to $425
• Positive Sentiment: Other analysts reiterate Buy on strong Q1 and growing confidence in the MariTide pipeline — continued analyst support could stabilize shares if clinical/readout progress continues. Analyst Reiterates Buy After Strong Q1
• Neutral Sentiment: Small PT change but conservative rating from Truist — Truist nudged its target to $327 and kept a Hold, a reminder that some firms view upside as limited near term. Truist Raises Price Target Slightly
• Neutral Sentiment: FY‑2026 guidance set in a range that many investors saw as roughly in‑line with expectations — guidance reduced uncertainty but the midpoint sits near consensus, limiting an immediate bullish catalyst. Amgen Reports First Quarter 2026 Financial Results
• Negative Sentiment: FDA proposal to withdraw Tavneos for alleged trial data issues — this is a material regulatory and reputational risk that can affect near‑term valuation and investor confidence. FDA Tavneos Proposal Puts Amgen’s Data Integrity In Focus
• Negative Sentiment: Investor pullback on “generally in‑line” quarter plus aggressive MariTide expansion — markets punished the stock as investors weighed near‑term dilution from R&D/launch spending despite long‑term upside. Amgen Is ‘Aggressively Expanding’ In Obesity Treatment

Hedge Funds Weigh In On Amgen

A number of hedge funds have recently modified their holdings of the company. Sfam LLC purchased a new position in shares of Amgen during the 4th quarter valued at $38,000. Advocate Investing Services LLC purchased a new position in shares of Amgen during the 4th quarter valued at $39,000. Garton & Associates Financial Advisors LLC purchased a new position in shares of Amgen during the 4th quarter valued at $52,000. Binnacle Investments Inc lifted its stake in shares of Amgen by 26.1% during the 3rd quarter. Binnacle Investments Inc now owns 208 shares of the medical research company’s stock valued at $59,000 after buying an additional 43 shares in the last quarter. Finally, Itau Unibanco Holding S.A. lifted its stake in shares of Amgen by 21.2% during the 4th quarter. Itau Unibanco Holding S.A. now owns 189 shares of the medical research company’s stock valued at $62,000 after buying an additional 33 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.